Get the app
US › Healthcare

Nkarta Inc (NKTX)

US · Healthcare · Biotechnology

$2.81-2.09%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-40.4M
EPS
$-0.54
EPS estimate
$-0.39

EPS came in at -0.54 against a street estimate of -0.39 — a miss of 38.5%.

Key statistics

Market cap
$208.4M
Forward P/E
0.0
P/B
0.84
Book value
$3.46
EPS (TTM)
$-1.59
52-week high
$3.72
52-week low
$1.70
50-day MA
$2.62
200-day MA
$2.46
Beta
0.97

Analyst view

Analysts rate Nkarta Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $10.83.

Shareholding

Insiders
4.88%
Institutions
82.71%

Largest institutional holders

FundStake
RA Capital Management, LLC15.09%
BlackRock Inc6.29%
NEA Management Company, LLC4.98%
Samsara BioCapital, LLC4.90%
SR ONE CAPITAL MANAGEMENT, LP4.65%
GSK PLC4.40%
Monaco Asset Management3.31%
Citadel Advisors Llc3.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nkarta Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.